Search

Search Constraints

You searched for: Date 2022 Author/Creator Capdevila, Jaume

Search Results

2. Cabozantinib for previously treated radioiodine‐refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC‐311 trial. Issue 24 (19th October 2022)

4. Clinical activity of CC‐90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies. Issue 17 (23rd June 2022)

5. Corrigendum to 'Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study' [European Journal of Cancer 154 (2021) 246-252]. (January 2022)

6. Development of a quality of life questionnaire for patients with pancreatic neuroendocrine tumours (the PANNET module). (13th February 2022)

8. Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy. (7th March 2022)

9. Quality of life and late toxicity after short-course radiotherapy followed by chemotherapy or chemoradiotherapy for locally advanced rectal cancer – The RAPIDO trial. (June 2022)